Carfilzomib prevented BCMA degradation, increased target density, and improved CAR T susceptibility by ~26%–28% in vitro, while enhancing xenograft antitumor activity without worsening T-cell ...

Hepta refractory multiple myeloma is marked by antigen loss, genomic complexity, and 12.8 month median survival in multi centre data.

Minimal residual disease (MRD) refers to the small number of myeloma cells that may remain after treatment and are not detectable using conventional response criteria. In multiple myeloma, MRD ...

Princeton, New Jersey Thursday, February 19, 2026, 11:00 Hrs [IST] ...

The NDA is supported by data from the EXCALIBER-RRMM trial, which evaluated the safety and efficacy of iberdomide, an investigational cereblon E3 ligase modulator.

FDA accepts and grants priority review to Bristol Myers' NDA for iberdomide combo in relapsed or refractory multiple myeloma. A decision is due on Aug. 17, 2026.

The FDA has started a priority review of iberdomide as an add-on to Johnson & Johnson and Genmab's anti-CD38 antibody Darzalex (daratumumab) and dexamethasone, a standard regimen for relapsed or ...

The FDA has accepted Bristol Myers Squibb (BMS)’s New Drug Application (NDA) for iberdomide for relapsed or refractory ...

FDA has accepted the NDA for BMS's Iberdomide, an oral agent targetting relapsed/refractory multiple myeloma.

Veteran actor Pravina Deshpande has passed away at the age of 60. She was undergoing treatment for multiple myeloma, a form ...

Multiple myeloma is a cancer that occurs when a type of white blood cell grows out of control, causing low blood counts, bone and calcium problems, frequent infections and kidney damage. According to ...

Genmab will hold a conference call to discuss the full year results for 2025 today, February 17, 2026 at 6:00 pm CET, 5:00 pm GMT, 12:00 pm EST. To join the call please use the below registration link ...